Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor infiltrating lymphocytes LN-145-S1
- Development stage
- Unknown
- Lead developer
- Iovance Biotherapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
LN-145-S1 is an investigational, autologous tumor-infiltrating lymphocyte (TIL) therapy developed by Iovance Biotherapeutics. It is a second-generation version of LN-145, manufactured using a modified process that selects for a specific subset of T cells expressing PD-1, which are believed to be enriched for tumor-reactive clones. The therapy is produced as a cryopreserved infusion product at centralized GMP facilities. The treatment protocol involves a non-myeloablative (NMA) lymphodepletion preparative regimen, followed by the infusion of the TIL product and subsequent administration of interleukin-2 (IL-2) to support T-cell expansion and activity. LN-145-S1 is currently being evaluated in Phase II clinical trials for various refractory or relapsed solid tumors, including ovarian cancer, triple-negative breast cancer, and various sarcomas.
- Other names
- autologous tumor infiltrating lymphocytes LN-145-S1PD-1 selected TILsPD1 selected TILsPD 1 selected TILsPD-1 selected tumor-infiltrating lymphocytesPD1 selected tumor-infiltrating lymphocytesPD 1 selected tumor-infiltrating lymphocytes
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on autologous tumor infiltrating lymphocytes LN-145-S1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor infiltrating lymphocytes LN-145-S1.